期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

P2Y12受体拮抗剂在缺血性脑卒中及短暂性脑缺血发作防治中的应用 被引量：3

The Use of P2Y12 Receptor Antagonists in the Prevention and Treatment of Ischemic Stroke and Transient Ischemic Attack
原文传递
导出
摘要 P2Y12受体拮抗剂是一类作用于血小板P2Y12受体、对5’-二磷酸腺苷(ADP)介导的血小板聚集起抑制作用、临床常用的抗血小板药物。P2Y12受体拮抗剂在缺血性脑血管病预防和治疗中的作用机制是目前临床研究的热点问题。文中对常见P2Y12受体拮抗剂在缺血性脑卒中及短暂性脑缺血发作中的作用及研究进展做综述。 P2Y12 receptor antagonists are a group of common used antiplatelet drugs which were acting on platelet P2Y12 receptor and inhibit platelet aggregation induced by adenosine 5＇-diphosphate（ADP）. The use of P2Y12 receptor antagonists in the prevention and treatment of ischemic cerebral vascular disease is one of the clinical hotspots. The research status of the use of P2Y12 receptor antagonists in the prevention and treatment of ischemic stroke and transient ischemic attack（TIA） were reviewed.
作者 吴琼 张忠玲
机构地区 哈尔滨医科大学附属第一医院神经内科
出处 《中国临床神经科学》 2018年第1期70-73,共4页 Chinese Journal of Clinical Neurosciences
关键词 P2Y12受体拮抗剂 缺血性脑卒中 短暂性脑缺血发作 氯吡格雷抵抗 替格瑞洛 P2Y12 receptor antagonist ischemic stroke transient ischemic attack clopidogrelresistance ticagrelor
分类号 R743 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献2

二级参考文献51

  • 1Kelly RP, Close SL, Farid NA, Witers K J, Shen L, Natanegara F, et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. BrJ Clin Pharmaco12012; 73: 93-105.
  • 2Boggon R, van Staa TP, Timmis A, Hemingway H, Ray KK, Begg A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction -- a hospital registry - primary care linked cohort (MINAP- GPRD). Eur Heart J 2011; 32: 2376-86.
  • 3Perry CG, Shuldiner AR. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet 2013: 58: 339-45.
  • 4Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coil Cardiol 2005; 45: 1157-64.
  • 5Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topoi EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coil Cardiol 2005; 45: 246-51.
  • 6Ford NF. Clopidogrel resistance: pharmacokinetic or pharmaco- genetic? J Clin Pharmacol 2009; 49: 506-12.
  • 7Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci 2013; 123: 143-54.
  • 8Jiang XL, Samant S, Lesko U, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet 2015; 54: 147 - 66.
  • 9Kazui M, Nishiya Y, Ishizuka 1, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-9.
  • 10Wang XD, Deng XY, Chen J, Li JL, Chen X, Zhao LZ, et al. Single nucleotide polymorphisms of the pregnane X receptor gene in Han Chinese and a comparison with other ethnic populations. Pharma- cology 2008; 81: 350-4.

共引文献38

同被引文献24

引证文献3

二级引证文献4

中国临床神经科学
2018年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部